dexcom inc. - DXCM
DXCM
Close Chg Chg %
62.37 -0.15 -0.24%
Closed Market
62.22
-0.15 (0.24%)
Volume: 2.41M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: dexcom inc. - DXCM
DXCM Key Data
| Open $61.50 | Day Range 60.57 - 62.86 |
| 52 Week Range 54.11 - 89.98 | Market Cap $23.95B |
| Shares Outstanding 384.87M | Public Float 379.46M |
| Beta 1.56 | Rev. Per Employee N/A |
| P/E Ratio 29.78 | EPS $2.14 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 4.02M |
DXCM Performance
| 1 Week | -0.05% | ||
| 1 Month | -8.63% | ||
| 3 Months | -6.49% | ||
| 1 Year | 3.99% | ||
| 5 Years | -31.91% |
DXCM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
31
Full Ratings ➔
About dexcom inc. - DXCM
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.
DXCM At a Glance
DexCom, Inc.
6340 Sequence Drive
San Diego, California 92121
| Phone | 1-858-200-0200 | Revenue | 4.66B | |
| Industry | Medical Specialties | Net Income | 836.30M | |
| Sector | Health Technology | 2025 Sales Growth | 15.596% | |
| Fiscal Year-end | 12 / 2026 | Employees | 11,100 | |
| View SEC Filings |
DXCM Valuation
| P/E Current | 29.849 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 31.764 |
| Price to Sales Ratio | 5.773 |
| Price to Book Ratio | 9.301 |
| Price to Cash Flow Ratio | 18.68 |
| Enterprise Value to EBITDA | 22.606 |
| Enterprise Value to Sales | 5.642 |
| Total Debt to Enterprise Value | 0.053 |
DXCM Efficiency
| Revenue/Employee | 420,000.00 |
| Income Per Employee | 75,342.342 |
| Receivables Turnover | 3.614 |
| Total Asset Turnover | 0.727 |
DXCM Liquidity
| Current Ratio | 1.883 |
| Quick Ratio | 1.589 |
| Cash Ratio | 0.933 |
DXCM Profitability
| Gross Margin | 60.011 |
| Operating Margin | 19.558 |
| Pretax Margin | 23.346 |
| Net Margin | 17.939 |
| Return on Assets | 13.042 |
| Return on Equity | 34.497 |
| Return on Total Capital | 20.221 |
| Return on Invested Capital | 22.074 |
DXCM Capital Structure
| Total Debt to Total Equity | 50.608 |
| Total Debt to Total Capital | 33.603 |
| Total Debt to Total Assets | 21.92 |
| Long-Term Debt to Equity | 49.822 |
| Long-Term Debt to Total Capital | 33.08 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Dexcom Inc. - DXCM
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.91B | 3.62B | 4.03B | 4.66B | |
Sales Growth
| +18.84% | +24.49% | +11.34% | +15.60% | |
Cost of Goods Sold (COGS) incl D&A
| 1.03B | 1.34B | 1.60B | 1.86B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 155.90M | 186.00M | 217.70M | 251.80M | |
Depreciation
| 144.10M | 147.40M | 181.20M | 219.00M | |
Amortization of Intangibles
| 11.80M | 38.60M | 36.50M | 32.80M | |
COGS Growth
| +34.66% | +29.71% | +19.38% | +16.41% | |
Gross Income
| 1.88B | 2.28B | 2.43B | 2.80B | |
Gross Income Growth
| +11.61% | +21.60% | +6.61% | +15.06% | |
Gross Profit Margin
| +64.46% | +62.97% | +60.29% | +60.01% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.48B | 1.68B | 1.83B | 1.89B | |
Research & Development
| 484.20M | 497.70M | 545.70M | 594.90M | |
Other SG&A
| 1.00B | 1.19B | 1.29B | 1.29B | |
SGA Growth
| +4.93% | +13.39% | +8.82% | +2.97% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| 391.20M | 597.70M | 600.00M | 911.80M | |
Non Operating Income/Expense
| 18.20M | 133.00M | 128.00M | 194.90M | |
Non-Operating Interest Income
| - | 135.00M | 134.20M | 112.70M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 18.60M | 20.30M | 19.00M | 18.30M | |
Interest Expense Growth
| -81.46% | +9.14% | -6.40% | -3.68% | |
Gross Interest Expense
| 18.60M | 20.30M | 19.00M | 18.30M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 390.80M | 710.40M | 709.00M | 1.09B | |
Pretax Income Growth
| +124.73% | +81.78% | -0.20% | +53.51% | |
Pretax Margin
| +13.43% | +19.61% | +17.58% | +23.35% | |
Income Tax
| 49.60M | 168.90M | 132.80M | 252.10M | |
Income Tax - Current - Domestic
| 58.70M | 167.20M | 173.90M | 44.20M | |
Income Tax - Current - Foreign
| 12.50M | 56.70M | 2.70M | 25.70M | |
Income Tax - Deferred - Domestic
| (21.90M) | (79.10M) | (57.20M) | 185.70M | |
Income Tax - Deferred - Foreign
| 300.00K | 24.10M | 13.40M | (3.50M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 341.20M | 541.50M | 576.20M | 836.30M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 341.20M | 541.50M | 576.20M | 836.30M | |
Net Income Growth
| +120.56% | +58.70% | +6.41% | +45.14% | |
Net Margin Growth
| +11.73% | +14.95% | +14.29% | +17.94% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 341.20M | 541.50M | 576.20M | 836.30M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 341.20M | 541.50M | 576.20M | 836.30M | |
EPS (Basic)
| 0.8762 | 1.4028 | 1.4639 | 2.1433 | |
EPS (Basic) Growth
| +119.10% | +60.10% | +4.36% | +46.41% | |
Basic Shares Outstanding
| 389.40M | 386.00M | 393.60M | 390.20M | |
EPS (Diluted)
| 0.7981 | 1.3022 | 1.424 | 2.0895 | |
EPS (Diluted) Growth
| +106.55% | +63.16% | +9.35% | +46.73% | |
Diluted Shares Outstanding
| 427.50M | 425.50M | 412.70M | 405.50M | |
EBITDA
| 547.10M | 783.70M | 817.70M | 1.16B | |
EBITDA Growth
| +48.75% | +43.25% | +4.34% | +42.30% | |
EBITDA Margin
| +18.80% | +21.64% | +20.28% | +24.96% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 87.833 | |
| Number of Ratings | 31 | Current Quarters Estimate | 0.605 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | 2.486 | |
| Last Quarter’s Earnings | 0.47 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 2.09 | Next Fiscal Year Estimate | 2.99 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 23 | 23 | 26 | 26 |
| Mean Estimate | 0.60 | 0.67 | 2.49 | 2.99 |
| High Estimates | 0.65 | 0.72 | 2.59 | 3.29 |
| Low Estimate | 0.55 | 0.61 | 2.38 | 2.73 |
| Coefficient of Variance | 4.22 | 4.51 | 2.28 | 4.68 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 22 | 22 | 24 |
| OVERWEIGHT | 4 | 4 | 3 |
| HOLD | 4 | 4 | 5 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 1 | 1 | 1 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Dexcom Inc. - DXCM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Dexcom Inc. - DXCM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 11, 2026 | Jon Curtis Coleman EVP, Chief Commercial Officer | 112,635 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Kevin Ronald Sayer Executive Chair; Director | 441,739 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Kevin Ronald Sayer Executive Chair; Director | 409,241 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.1 per share | 27,869,312.10 |
| Mar 11, 2026 | Michael Jon Brown EVP, Chief Legal Officer | 137,929 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Michael Jon Brown EVP, Chief Legal Officer | 114,604 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.1 per share | 7,804,532.40 |
| Mar 11, 2026 | Jacob S. Leach President, CEO, and Director; Director | 441,567 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Jacob S. Leach President, CEO, and Director; Director | 421,810 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.1 per share | 28,725,261.00 |
| Mar 11, 2026 | Jereme M Sylvain EVP, Chief Financal Officer | 172,242 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Jereme M Sylvain EVP, Chief Financal Officer | 153,292 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.1 per share | 10,439,185.20 |
| Mar 11, 2026 | Sadie M Stern EVP, Chief HR Officer | 148,709 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2026 | Sadie M Stern EVP, Chief HR Officer | 131,510 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $68.1 per share | 8,955,831.00 |
| Jul 18, 2025 | Mark G. Foletta Director | 53,879 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.17 per share | 4,588,874.43 |
| Jul 18, 2025 | Mark G. Foletta Director | 53,871 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $86.03 per share | 4,634,522.13 |